Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 4Active not recruiting 2

Sponsor Class

INDUSTRY 5NETWORK 1

Study Type

Interventional 6

Sponsor

Conditions

Breast Neoplasms 3092Neoplasms 2436Carcinoma, Non-Small-Cell Lung 1863Prostatic Neoplasms 1617Colorectal Neoplasms 1422Lung Neoplasms 1292Multiple Myeloma 927Neoplasm Metastasis 919Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 847Ovarian Neoplasms 799Melanoma 783Carcinoma, Hepatocellular 736Stomach Neoplasms 639Brain Neoplasms 635Recurrence 633Squamous Cell Carcinoma of Head and Neck 630Head and Neck Neoplasms 609Glioblastoma 566Lymphoma 539Uterine Cervical Neoplasms 537Triple Negative Breast Neoplasms 504Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Carcinoma, Renal Cell 497Hematologic Neoplasms 462Urinary Bladder Neoplasms 459Endometrial Neoplasms 459Colonic Neoplasms 441Lymphoma, Non-Hodgkin 435Sarcoma 434

Interventions

tremelimumab 1durvalumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Solid Malignancies × 1 year × Clear all
NCT06725381 2026-05-08

A Phase 1 Study of SKB571 in Subjects With Advanced Solid Tumors

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 1 Recruiting
138 enrolled

Solid Malignancies

NCT07505771 2026-04-06

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

Immunome, Inc.

Phase EARLY_PHASE1 Recruiting
105 enrolled

Solid Malignancies

NCT02537418 2026-03-27

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Canadian Cancer Trials Group

Phase 1 Active not recruiting
153 enrolled

Solid Malignancies

NCT05006794 2026-01-07

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Gilead Sciences

Phase 1 Active not recruiting
145 enrolled

Solid Malignancies

NCT06600789 2025-11-03

A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

Carrick Therapeutics Limited

Phase 1/2 Recruiting
50 enrolled

Solid Malignancies

NCT06933069 2025-09-11

Safety and Tolerability of CMAB017 In Patients With Advanced Solid Tumors

Taizhou Mabtech Pharmaceutical Co.,Ltd

Phase 1 Recruiting
55 enrolled

Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡